Effectiveness of pentoxifylline in contrast induced nephropathy

Effectiveness of oral pentoxifylline for the prevention of contrast nephropathy in CKD patients undergoing coronary angiography

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015102624713N1

Enrollment

Registered

2016-03-09

Start date

2016-01-09

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Contrast Nephropathy. Renal failure

Interventions

Intervention 1: In the control group N-acetylcysteine 1200 mg administered every 12 hours in addition to hydration will be prescribed. Intervention 2: In the intervention group, prescribed pentoxifyl

Treatment - Drugs

In the control group N-acetylcysteine 1200 mg administered every 12 hours in addition to hydration will be prescribed

In the intervention group, prescribed pentoxifylline 400 mg every 8 hours plus hydration and NAC In the control group , prescription N-acetylcysteine ??1200 mg every 12 hours is recommended in addit

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria of ckd patients with angiography and cardiac catheterization indication include:Age greater than 18 and less than 75 years,Patient satisfaction for the study Exclusion criteria include : problems in patients follow up, treatment with theophylline, furosemide, mannitol or dopamine in last one month,use of Nonsteroidal anti-inflammatory drugs, aminoglycosides, N-acetylcysteine drugs,Renal failure patients with serum creatinine equal to or less than 1.5 mg per deciliter, Patients with an allergy to contrast material, Patients with Multiple myeloma, Pulmonary edema, Uncontrolled hypertension, patient required emergency angiography, diagnostic use of radiocontrast material for patient in the last 2 months of other diagnostic reasons, congestive heart failure,pregnancy, lactation Sensitivity to the NAC or pentoxifylline

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Serum Creatine. Timepoint: at admission, 24 h after intervention. Method of measurement: blood test based on miligram on decilitre.	—

Secondary

Measure	Time frame
Contrast Nephropathy. Timepoint: 24 houres. Method of measurement: blood test based on miligram on decilitre.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahmoud Kordi

Zahedan Medical University

gharibeh.0001@gmail.com+98 54 3328 7533

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026